Transforming Clinical Research – Insights from Rauno Oja, CEO of EGeen International Corporation In this episode, Rauno Oja, CEO of EGeen International Corporation, shares his distinctive perspective on the pharmaceutical and clinical research industry. With a background in business administration rather than medicine, Rauno entered the sector immediately after graduation and has since built one of Europe’s fastest-growing contract research organizations (CROs). Rauno discusses the persistent inefficiencies that frustrate him most in clinical trials, the limitations of technology when applied without clear strategy, and why AI alone cannot solve the industry’s challenges. He explains that true acceleration comes from direction first, tools second. Key topics include: EGeen’s evolution from an Estonian genome initiative to a full-service European CRO offering feasibility, site selection, regulatory support, patient recruitment, monitoring, project management, data management, biostatistics, and medical writingThe strategic advantage of maintaining on-site monitoring and building genuine investigator relationships in an increasingly remote industryHow early, collaborative feasibility and mock protocol exercises with sites prevent costly delays and amendmentsProven success in outperforming larger competitors in patient enrollment speed and volumeA balanced view on AI and digital tools: powerful enablers when guided by experience and clear objectives Rauno demonstrates that diverse leadership backgrounds, proactive site partnership, and disciplined use of technology can deliver faster, higher-quality clinical trials without compromising standards. Ideal for clinical operations leaders, sponsor teams, investigators, and anyone seeking practical ways to improve trial efficiency and outcomes. Tags: pharmaceutical, clinical research, CRO, patient recruitment, site engagement, trial efficiency, AI in clinical trials, Rauno Oja, EGeen International Corporation, clinical operations, feasibility studies, monitoring, biotech
